BR112022018948A2 - Métodos de tratamento de lesão pulmonar com inibidores de cgrp - Google Patents

Métodos de tratamento de lesão pulmonar com inibidores de cgrp

Info

Publication number
BR112022018948A2
BR112022018948A2 BR112022018948A BR112022018948A BR112022018948A2 BR 112022018948 A2 BR112022018948 A2 BR 112022018948A2 BR 112022018948 A BR112022018948 A BR 112022018948A BR 112022018948 A BR112022018948 A BR 112022018948A BR 112022018948 A2 BR112022018948 A2 BR 112022018948A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
lung injury
cgrp
patient
Prior art date
Application number
BR112022018948A
Other languages
English (en)
Inventor
John Donnie Mcgrath St
Coric Vladimir
M Conway Charles
M Caldwell Reese
M Schnittman Steven
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of BR112022018948A2 publication Critical patent/BR112022018948A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE LESÃO PULMONAR COM INIBIDORES DE CGRP. A presente invenção refere-se a um método para o tratamento de COVID-19 em um paciente com necessidade de tal tratamento, em que o método inclui a administração ao paciente de uma quantidade terapeuticamente eficaz de inibidor de CGRP. Também é fornecida uma composição farmacêutica para o tratamento de COVID-19 em um paciente com necessidade de tal tratamento, em que a composição farmacêutica inclui uma quantidade terapeuticamente eficaz de inibidor de CGRP.
BR112022018948A 2020-03-23 2021-03-22 Métodos de tratamento de lesão pulmonar com inibidores de cgrp BR112022018948A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062993451P 2020-03-23 2020-03-23
PCT/US2021/023388 WO2021194918A1 (en) 2020-03-23 2021-03-22 Methods of treating pulmonary injury with cgrp inhibitors

Publications (1)

Publication Number Publication Date
BR112022018948A2 true BR112022018948A2 (pt) 2022-11-16

Family

ID=77892226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018948A BR112022018948A2 (pt) 2020-03-23 2021-03-22 Métodos de tratamento de lesão pulmonar com inibidores de cgrp

Country Status (11)

Country Link
US (1) US20230285390A1 (pt)
EP (1) EP4126002A4 (pt)
JP (1) JP2023532617A (pt)
KR (1) KR20220158245A (pt)
CN (1) CN115697378A (pt)
AU (1) AU2021244192A1 (pt)
BR (1) BR112022018948A2 (pt)
CA (1) CA3176072A1 (pt)
IL (1) IL296688A (pt)
MX (1) MX2022011725A (pt)
WO (1) WO2021194918A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151214A1 (en) * 2021-09-20 2023-03-22 Universidade Nova De Lisboa Rimegepant for treatment of human coronavirus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015767A (zh) * 2008-01-17 2011-04-13 胡马斯有限公司 针对SARS-CoV的交叉中和人单克隆抗体及其使用方法
EP3142699A4 (en) * 2014-05-16 2017-11-22 Salk Institute for Biological Studies Compositions and methods for treating metabolic disorders
GB201519196D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
JP2021519288A (ja) * 2018-03-25 2021-08-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． Ｃｇｒｐ関連障害のためのリメゲパント

Also Published As

Publication number Publication date
WO2021194918A1 (en) 2021-09-30
AU2021244192A1 (en) 2022-11-17
KR20220158245A (ko) 2022-11-30
CN115697378A (zh) 2023-02-03
US20230285390A1 (en) 2023-09-14
JP2023532617A (ja) 2023-07-31
EP4126002A4 (en) 2024-04-10
IL296688A (en) 2022-11-01
CA3176072A1 (en) 2021-09-30
MX2022011725A (es) 2022-10-10
EP4126002A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112021018739A8 (pt) Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112023002573A2 (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
BR112022018948A2 (pt) Métodos de tratamento de lesão pulmonar com inibidores de cgrp
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112012025879A2 (pt) compostos de triazol como inibidores de ksp
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
BR112023017689A2 (pt) Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing